Non-Bacterial Infection of Nervous System DRG 098 Reimbursement

DRG 098 encompasses non-bacterial infections of the nervous system except viral meningitis when a Complication or Comorbidity is present, covering conditions that increase clinical complexity and resource use. Proper assignment to this Diagnosis-Related Group affects inpatient reimbursement under Centers for Medicare & Medicaid Services payment methodology because severity classification drives relative weight and payment.

DRG 098 Overview

DRG 098 covers non-bacterial infections of the nervous system other than viral meningitis when a Complication or Comorbidity is present, such as viral encephalitis or fungal central nervous system infection with additional clinical complexity. This Diagnosis-Related Group groups patients with higher resource use than uncomplicated cases because the Complication or Comorbidity increases diagnostic, monitoring, and treatment needs. It matters for Medicare payment because assignment to this Diagnosis-Related Group affects inpatient prospective payment and hospital reimbursement under Centers for Medicare & Medicaid Services rules. Accurate coding and documentation determine whether a case is assigned to DRG 098 rather than to a lower-severity group.

Acute-management randomized or controlled trials examining adjunctive anti-inflammatory or immunomodulatory therapies in hospitalized patients diagnosed with non-bacterial central nervous system infections (excluding viral meningitis), focusing on patients with altered mental status, focal neurologic deficits, or intracranial complications. These studies enroll patients during the inpatient stay to evaluate short-term endpoints such as time to neurologic stabilization, need for ICU-level care, length of stay, and in-hospital complication rates. Results inform clinicians about interventions that could shorten acute resource use and help payers anticipate and manage high-cost episodes of care associated with complicated CNS infections with comorbid conditions.
Comparative effectiveness and diagnostic-optimization studies that assess different combinations of imaging strategies, cerebrospinal fluid testing algorithms, and antimicrobial stewardship approaches in adults presenting with suspected non-bacterial CNS infection and concurrent comorbidities (CC). These observational or pragmatic trial designs compare accuracy, time-to-diagnosis, antibiotic exposure, and downstream resource utilization across diagnostic pathways in heterogeneous inpatient populations. Such research is relevant to providers and payers because more efficient, accurate diagnostic approaches can reduce unnecessary empiric therapies, lower lengths of stay, and decrease costs from misdirected treatments while preserving patient safety.
Post-discharge prospective cohort and outcomes research evaluating functional recovery, readmission risk, and long-term neurologic sequelae among survivors of non-bacterial CNS infections with complicating comorbidities, including studies of rehabilitation needs, cognitive outcomes, and health-related quality of life over 6–12 months. These studies follow patients after hospital discharge to quantify durable disability, service utilization (rehab, home health, readmissions), and predictors of poor outcomes, stratified by initial inpatient severity and complications. This information helps discharge planners, rehabilitation providers, and payers plan longitudinal care pathways and allocate resources for post-acute services to reduce readmissions and improve value of care for this DRG.

Acute-management randomized or controlled trials examining adjunctive anti-inflammatory or immunomodulatory therapies in hospitalized patients diagnosed with non-bacterial central nervous system infections (excluding viral meningitis), focusing on patients with altered mental status, focal neurologic deficits, or intracranial complications. These studies enroll patients during the inpatient stay to evaluate short-term endpoints such as time to neurologic stabilization, need for ICU-level care, length of stay, and in-hospital complication rates. Results inform clinicians about interventions that could shorten acute resource use and help payers anticipate and manage high-cost episodes of care associated with complicated CNS infections with comorbid conditions.
Comparative effectiveness and diagnostic-optimization studies that assess different combinations of imaging strategies, cerebrospinal fluid testing algorithms, and antimicrobial stewardship approaches in adults presenting with suspected non-bacterial CNS infection and concurrent comorbidities (CC). These observational or pragmatic trial designs compare accuracy, time-to-diagnosis, antibiotic exposure, and downstream resource utilization across diagnostic pathways in heterogeneous inpatient populations. Such research is relevant to providers and payers because more efficient, accurate diagnostic approaches can reduce unnecessary empiric therapies, lower lengths of stay, and decrease costs from misdirected treatments while preserving patient safety.
Post-discharge prospective cohort and outcomes research evaluating functional recovery, readmission risk, and long-term neurologic sequelae among survivors of non-bacterial CNS infections with complicating comorbidities, including studies of rehabilitation needs, cognitive outcomes, and health-related quality of life over 6–12 months. These studies follow patients after hospital discharge to quantify durable disability, service utilization (rehab, home health, readmissions), and predictors of poor outcomes, stratified by initial inpatient severity and complications. This information helps discharge planners, rehabilitation providers, and payers plan longitudinal care pathways and allocate resources for post-acute services to reduce readmissions and improve value of care for this DRG.

OpenPayer

Summary & Overview

Non-Bacterial Infection of Nervous System Except Viral Meningitis with CC: Inpatient Reimbursement Overview

DRG 098 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes